Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.
Robert GilmorePatrick HilleyAshish SrinivasanMatthew ChoyPeter De CruzPublished in: Journal of Crohn's & colitis (2021)
High-dose tofacitinib may have a role as salvage therapy in the setting of steroid-refractory ASUC. Prospective studies are required to determine the safety and efficacy of high-dose tofacitinib to determine whether it can be routinely recommended as primary or sequential salvage therapy in the setting of steroid-refractory ASUC.